OncoMatch/Clinical Trials/NCT06732232
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Is NCT06732232 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CD19/CD20/BCMA CAR-T for relapsed.
Treatment: CD19/CD20/BCMA CAR-T — This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) antigen positive (including weak, moderate, or strong positive) (positive (including weak, moderate, or strong positive))
The bone marrow flow cytometry results showed positive BCMA antigen (including weak positive, moderate positive, and strong positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD38 monoclonal antibody
Those who have received treatment with at least three different mechanisms of action (including anti-CD38 monoclonal antibodies, protease inhibitors, immunosuppressants, etc.) but have failed
Must have received: proteasome inhibitor
Those who have received treatment with at least three different mechanisms of action (including anti-CD38 monoclonal antibodies, protease inhibitors, immunosuppressants, etc.) but have failed
Must have received: immunosuppressant
Those who have received treatment with at least three different mechanisms of action (including anti-CD38 monoclonal antibodies, protease inhibitors, immunosuppressants, etc.) but have failed
Cannot have received: anti-CD45
Previously received any anti-CD45 or anti-CD3 treatment
Cannot have received: anti-CD3
Previously received any anti-CD45 or anti-CD3 treatment
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 8 weeks of signing the ICF, or plan to undergo ASCT during the study period
Subjects who receive autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of signing the ICF, or who plan to undergo ASCT during the study period
Cannot have received: allogeneic stem cell therapy
Subjects who have received allogeneic stem cell therapy in the past
Cannot have received: investigational drug or systemic anti-tumor treatment
Exception: within 4 weeks (or 5 half lives of the drug, whichever the researcher deems more appropriate) prior to single collection
Received any investigational drug or systemic anti-tumor treatment within 4 weeks (or 5 half lives of the drug, whichever the researcher deems more appropriate) prior to single collection
Lab requirements
Blood counts
Lymphocyte count >0.5 × 10^9/L; Neutrophil count ≥ 1.0 × 10^9/L; Hemoglobin ≥ 60g/L; Platelets ≥ 40 × 10^9/L
Kidney function
24-hour serum creatinine clearance rate ≥ 30 mL/min
Liver function
AST and ALT ≤ 2.5 x ULN; Total bilirubin ≤ 1.5 × ULN
Cardiac function
QTcF >470 ms excluded; NYHA Grade II and above heart failure excluded; LVEF ≤ 50% excluded; poorly controlled hypertension (SBP ≥ 150 mm Hg and/or DBP ≥ 95 mm Hg) excluded; clinically significant arrhythmias excluded
The blood biochemistry test results meet the following criteria: AST and ALT ≤ 2.5 x ULN; Total bilirubin ≤ 1.5 × ULN; 24-hour serum creatinine clearance rate ≥ 30 mL/min; Lipase and amylase ≤ 2 × ULN. The blood routine test meets the following criteria: Lymphocyte count >0.5 × 10^9/L; Neutrophil count ≥ 1.0 × 10^9/L; Hemoglobin ≥ 60g/L; Platelets ≥ 40 × 10^9/L. Cardiovascular diseases with clinical significance, including any of the following: QTcF >470 ms; NYHA Grade II and above heart failure; LVEF ≤ 50%; poorly controlled hypertension (SBP ≥ 150 mm Hg and/or DBP ≥ 95 mm Hg); clinically significant arrhythmias
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify